Tango Therapeutics, Inc. Director Purchases 37,800.00 in Stock
| TNGX Stock | USD 3.10 0.21 6.34% |
Slightly above 74% of Tango Therapeutics' investor base is looking to short. The analysis of the overall investor sentiment regarding Tango Therapeutics suggests that many traders are alarmed. Tango Therapeutics' investing sentiment can be driven by a variety of factors including economic data, Tango Therapeutics' earnings reports, geopolitical events, and overall market trends.
Tango |
Tango Therapeutics, Inc. Director Mace Rothenberg acquired 10,000 shares of Tango Therapeutics stock in a transaction on Monday, November 18th. The stock was purchased at an average price of 3.78 per share, with a total value of 37,800.00. Following the purchase, the director now owns 31,250 shares of the companys
Read at thelincolnianonline.com
 |
Tango Therapeutics Investor Sentiment by Other News Outlets
Investor sentiment, mood or attitude towards Tango Therapeutics can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Tango Therapeutics Fundamental Analysis
We analyze Tango Therapeutics' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Tango Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Tango Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Cash Flow From Operations
Cash Flow From Operations Comparative Analysis
Tango Therapeutics is currently under evaluation in cash flow from operations category among its peers. Operating Cash Flow reveals the quality of a company's reported earnings and is calculated by deducting company's income taxes from earnings before interest, taxes, and depreciation (EBITDA). In other words, Operating Cash Flow refers to the amount of cash a firm generates from the sales or products or from rendering services. Operating Cash Flow typically excludes costs associated with long-term investments or investment in marketable securities and is usually used by investors or analysts to check on the quality of a company's earnings.
Tango Therapeutics Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Tango Therapeutics stock to make a market-neutral strategy. Peer analysis of Tango Therapeutics could also be used in its relative valuation, which is a method of valuing Tango Therapeutics by comparing valuation metrics with similar companies.
Peers
Tango Therapeutics Related Equities
| DMAC | DiaMedica Therapeutics | 5.23 | ||||
| VCNX | Vaccinex | 1.50 | ||||
| VCYT | Veracyte | 1.23 | ||||
| VANI | Vivani Medical | 0.78 | ||||
| DNTH | Dianthus Therapeutics | 0.77 | ||||
| VCEL | Vericel Corp | 0.63 | ||||
| DOMH | Dominari Holdings | 1.20 | ||||
| DNLI | Denali Therapeutics | 2.53 | ||||
| EQ | Equillium | 4.11 | ||||
| VALN | Valneva SE | 6.16 |
Additional Tools for Tango Stock Analysis
When running Tango Therapeutics' price analysis, check to measure Tango Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Tango Therapeutics is operating at the current time. Most of Tango Therapeutics' value examination focuses on studying past and present price action to predict the probability of Tango Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Tango Therapeutics' price. Additionally, you may evaluate how the addition of Tango Therapeutics to your portfolios can decrease your overall portfolio volatility.